Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases

Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases

Diseases of the pulmonary alveolus, such as pulmonary fibrosis, are leading causes of morbidity and mortality, but exceedingly few drugs are developed for them. A major reason for this gap is that after inhalation, drugs are quickly whisked away from alveoli due to their high perfusion. To solve thi...

Full description

Bibliographic Details
Main Authors: Laura T. Ferguson, Xiaonan Ma, Jacob W. Myerson, Jichuan Wu, Patrick M. Glassman, Marco E. Zamora, Elizabeth D. Hood, Michael Zaleski, Mengwen Shen, Eno-Obong Essien, Vladimir V. Shuvaev, Jacob S. Brenner
Format: Article
Language:English
Published: Wiley-VCH 2023-03-01
Series:Advanced NanoBiomed Research
Subjects:
inhaled
nanomedicine
nintedanib; pulmonary fibrosis
surfactant
Online Access:https://doi.org/10.1002/anbr.202200106

Internet

https://doi.org/10.1002/anbr.202200106

Similar Items